Evidence map›Paper›PMID 38009611›Full record

ArticleJournal of medical virology2023

MORC3 represses the HCMV major immediate early promoter in myeloid cells in the absence of PML nuclear bodies.

Anna Champion, Alexandra Rowland, Levia Yee, Dick van den Boomen, Matthew Reeves, Paul Lehner, John Sinclair, Emma Poole

Open access · hybridAbstract read
In one paragraph

Article in Journal of medical virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Anna ChampionDepartment of Medicine, University of Cambridge, Cambridge, UK.
Alexandra RowlandDepartment of Medicine, University of Cambridge, Cambridge, UK.
Levia YeeDepartment of Medicine, University of Cambridge, Cambridge, UK.
Dick van den BoomenDepartment of Medicine, University of Cambridge, Cambridge, UK.
Matthew ReevesDivison of Virology, Department of Pathology, University of Cambridge, Cambridge, UK.
Paul LehnerDepartment of Medicine, University of Cambridge, Cambridge, UK.
John SinclairDepartment of Medicine, University of Cambridge, Cambridge, UK.
Emma PooleDepartment of Medicine, University of Cambridge, Cambridge, UK.
University of Cambridge · GB

Funding

Medical Research Council MR/K021087/1Medical Research Council MR/K021087/1/MRC_/Medical Research Council/United KingdomMedical Research Council MR/S00081X/1
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) can undergo either a latent or a lytic infection in cells of the myeloid lineage. Whilst the molecular mechanisms which determine the outcome of infection are far from clear, it is well established that a key factor is the differential regulation of the major immediate early promoter (MIEP) responsible for driving lytic immediate early gene expression. Using a myelomonocytic cell line stably transduced with a GFP reporter under the control of the MIEP, which recapitulates MIEP regulation in the context of virus infection, we have used an unbiased CRISPR-Cas9 sub-genomic, epigenetic library screen to identify novel cellular factors involved in MIEP repression during establishment and maintenance of latency in myeloid cells. One such cellular factor identified was MORC3. Consistent with MORC3 being a robust repressor of the MIEP, we show that THP1 cells devoid of MORC3 fail to establish latency. We also show that MORC3 is induced during latent infection, recruited to the MIEP and forms MORC3 nuclear bodies (MORC3-NBs) which, interestingly, co-localize with viral genomes. Finally, we show that the latency-associated functions of MORC3 are regulated by the deSUMOylase activity of the viral latency-associated LUNA protein likely to prevent untimely HCMV reactivation.

Indexed as

Adenosine TriphosphatasesCytomegalovirus InfectionsDNA-Binding ProteinsPromyelocytic Leukemia Nuclear BodiesCytomegalovirusGene Expression Regulation, ViralHumansMyeloid CellsVirus LatencyAdenosine TriphosphatasesDNA-Binding ProteinsMORC3 protein, humanhuman cytomegaloviruslatencyMORC3

Identifiers

PMID38009611
PMCPMC10952291
OpenAlexW4389037123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.